The cannabinoid receptors

Prostaglandins and Other Lipid Mediators

Volumn 68-69, Issue , 2002, Pages 619-631

  Howlett, Allyn C ^a,b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; Cannabinoid receptors; Presynaptic

Indexed keywords

1(3) PALMITOYLGLYCEROL; 1(3) STEAROYLGLYCEROL; 2 ARACHIDONOYLGLYCEROL; 2 ARACHIDONYLGLYCERYL ETHER; 2 LINOLENYLGLYCEROL; 2 LINOLEOYLGLYCEROL; 2 PALMITOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENYLATE CYCLASE; ANANDAMIDE; ARACHIDONYL 2' CHLOROETHYLAMIDE; ARACHIDONYLCYCLOPROPYLAMIDE; CALCIUM CHANNEL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DOCOSATETRAENOYLETHALONAMIDE; DRONABINOL; FATTY ACID DERIVATIVE; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; ICOSANOID; LIPID; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; O 1812; POTASSIUM CHANNEL; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG RECEPTOR; ENDOCANNABINOID; UNSATURATED FATTY ACID;

ARTICLE; COGNITIVE DEFECT; DYSPHORIA; ENZYME ACTIVATION; ENZYME INHIBITION; EUPHORIA; HUMAN; MEMORY DISORDER; METABOLISM; NONHUMAN; PROTEIN FAMILY; RECEPTOR AFFINITY; REGULATORY MECHANISM; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNTHESIS; TACHYCARDIA; ANIMAL; NERVOUS SYSTEM; PHYSIOLOGY; REVIEW;

ANIMALS; EICOSANOIDS; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HUMANS; NERVOUS SYSTEM; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

EID: 0036669799     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(02)00060-6     Document Type: Article

References (126)

1. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 65:1999;645.
2. Martin B.R., Mechoulam R., Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:1999;573.
3. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359:1998;1.
4. Palmer S.L., Khanolkar A.D., Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Curr. Pharm. Des. 6:2000;1381.
5. Devane W.A., Hanus L., Breuer A.et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946.
6. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032.
7. Mechoulam R., Ben-Shabat S., Hanus L.et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83.
8. Sugiura T., Kondo S., Sukagawa A.et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89.
9. 1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;3662.
10. Howlett AC, Barth F, Bonner TI, et al. International union of pharmacology classification of cannabinoid receptors. Pharmacol Rev, in press.
11. Abadji V., Lin S., Taha G.et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889.
12. Hillard C.J., Manna S., Greenberg M.J.et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289:1999;1427.
13. 1 vanilloid receptor "hybrid" ligands. Biochem. Biophys. Res. Commun. 281:2001;444.
14. Ben-Shabat S., Fride E., Sheskin T.et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353:1998;23.
15. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773.
16. 1 receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 134:2001;664.
17. Pertwee R.G. Neuropharmacology and therapeutic potential of cannabinoids. Addict. Biol. 5:2000;37.
18. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63:2001;569.
19. Porter A.C., Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther. 90:2001;45.
20. Abood M.E., Martin B.R. Neurobiology of marijuana abuse. Trends Pharmacol. Sci. 13:1992;20.
21. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58:1999;315.
22. Chaperon F., Thiébot M.-H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13:1999;243.
23. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:1986;75.
24. 9-tetrahydrocannabinol. Science. 177:1972;633.
25. 9-tetrahydrocannabinol. Pharmacology. 11:1974;3.
26. Huestis M.A., Gorelick D.A., Heishman S.J.et al. Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry. 58:2001;322.
27. Edery H., Grunfeld Y., Ben-Zvi Z., Mechoulam R. Structural requirements for cannabinoid activity. Ann. NY Acad. Sci. 191:1971;40.
28. Meschler J.P., Howlett A.C., Madras B.K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology. 156:2001;79.
29. 9-tetrahydrocannabinol in chimpanzees. Science. 179:1973;490.
30. Abel E.L. Retrieval of information after use of marihuana. Nature. 231:1971;58.
31. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav. Rev. 16:1992;55.
32. Wiley J., Balster R., Martin B.M. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276:1995;49.
33. Wiley J.L., Golden K.M., Ryan W.J., Balster R.L., Razdan R.K., Martin B.R. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol. Biochem. Behav. 58:1997;1139.
34. Wiley J.L., Barrett R.L., Lowe J., Balster R.L., Martin B.R. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995;669.
35. 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995;1.
36. Martin B.R., Compton D.R., Thomas B.F.et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471.
37. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209.
38. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586.
39. Rinaldi-Carmona M., Barth F., Héaulme M.et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240.
40. 9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264:1993;294.
41. 9-tetrahydrocannabinol (THC) on memory in the rat. Drug. Alcohol Depend. 28:1991;167.
42. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacol. 126:1996;125.
43. Lichtman A.H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol. 404:2000;175.
44. Elphick M.R., Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B. 356:2001;381.
45. 1. J. Comp. Neurol. 422:2000;159.
46. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393.
47. Hájos N., Katona I., Naiem S.S.et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci. 12:2000;3239.
48. Katona I., Sperlágh B., Maglóczky Z.et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience. 100:2000;797.
49. Katona I., Sperlágh B., Sík A.et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19:1999;4544.
50. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11:1999;4213.
51. Tsou K., Mackie K., Sañudo-Peña M.C., Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience. 93:1999;969.
52. Rodríguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in m-opioid receptor patches of the rat caudate putamen nucleus. J. Neurosci. 21:2001;823.
53. Schlicker E., Kathman M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 22:2001;565.
54. Giuffrida A., Parsons L.H., Kerr T.M., Rodríguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2:1999;358.
55. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J. Neurosci. 21:2001;RC174.
56. Maejima T., Hashimoto K., Yoshida T., Aiba A., Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron. 31:2001;463.
57. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729.
58. Stella N., Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425:2001;189.
59. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588.
60. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor. Trends Neurosci. 21:1998;521.
61. Hillard C.J., Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids. 108:2000;123.
62. Maccarrone M., van der Stelt M., Rossi A., Veldink G.A., Vliegenthart J.F.G., Finazzi Agrò A. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273:1998;32332.
63. Piomelli D., Beltramo M., Glasnapp S.et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA. 96:1999;5802.
64. Khanolkar A.D., Makriyannis A. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci. 65:1999;607.
65. Ueda N., Puffenbarger R.A., Yamamoto S., Deutsch D.G. The fatty acid amide hydrolase (FAAH). Chem. Phys. Lipids. 108:2000;107.
66. Egertová M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. R. Soc. Lond. B. 265:1998;2081.
67. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem. 273:1998;16865.
68. 1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 336:1997;295.
69. 2 receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins Leukot. Essent. Fatty Acids. 59:1998;111.
70. Howlett A.C., Mukhopadhyay S. Cellular signal transduction by anandamide. Chem. Phys. Lipids. 108:2000;53.
71. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352.
72. Pinto J.C., Potie F., Rice K.C.et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:1994;516.
73. Childers S.R., Sexton T., Roy M.B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711.
74. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656.
75. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498.
76. 2) cannabinoid receptors. Mol. Pharmacol. 48:1995;288.
77. Sugiura T., Kodaka T., Kondo S.et al. Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma × glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 233:1997;207.
78. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552.
79. 2 receptors. Mol. Pharmacol. 48:1995;443.
80. Hampson A.J., Bornheim L.M., Scanziani M.et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70:1998;671.
81. 2+ channel current. Am. J. Physiol. 276:1999;H2085.
82. McAllister S.D., Griffin G., Satin L.S., Abood M.E. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J. Pharmacol. Exp. Ther. 291:1999;618.
83. Bouaboula M., Poinot-Chazel C., Bourrié B.et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312:1995;637.
84. Bouaboula M., Bourrié B., Rinaldi-Carmona M., Shire D., Le Fur G., Casellas P. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270:1995;13973.
85. Patel N.A., Moldow R.L., Patel J.A., Wu G., Chang S.L. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Res. 797:1998;225.
86. i-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett. 449:1999;61.
87. Wartmann M., Campbell D., Subramanian A., Burstein S.H., Davis R.J. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359:1995;133.
88. Derkinderen P., Toutant M., Burgaya F.et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science. 273:1996;1719.
89. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54:1998;834.
90. Guzmán M., Sánchez C. Effects of cannabinoids on energy metabolism. Life Sci. 65:1999;657.
91. 2++ transient in NG108-15 cells. J. Biochem. 122:1997;890.
92. 2+ in neuroblastoma × glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 229:1996;58.
93. Sugiura T., Kodaka T., Nakane S.et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor: structure-activity relationship of 2-arachidonoylglycerol ether-linked analogues, and related compounds. J. Biol. Chem. 274:1999;2794.
94. Stefano G.B., Liu Y., Goligorsky M.S. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem. 271:1996;19238.
95. Prevot V., Rialas C.M., Croix D.et al. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Res. 790:1998;236.
96. Stefano G.B., Salzet M., Magazine H.I., Bilfinger T.V. Antagonism of LPS and IFN-γ induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. J. Cardiovasc. Pharmacol. 31:1998;813.
97. Fimiani C., Mattocks D., Cavani F.et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell. Signal. 11:1999;189.
98. 2+ in endothelial cells. Br. J. Pharmacol. 126:1999;1593.
99. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids. 108:2000;169.
100. Cabral G.A. Marijuana and cannabinoids: effects on infections, immunity, and AIDS. J. Cannabis Ther. 1:2001;61.
101. 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J. Pharmacol. Exp. Ther. 273:1995;1216.
102. McCoy K.L., Matveyeva M., Carlisle S.J., Cabral G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther. 289:1999;1620.
103. 2 receptor. Eur. J. Pharmacol. 396:2000;141.
104. Sacerdote P., Massi P., Panerai A.E., Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 109:2000;155.
105. 9-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur. J. Pharmacol. 387:2000;343.
106. 9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 165:2000;373.
107. 9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-g, IL-12, and IL-12 receptor b2 responses to Legionella pneumophila infection. J. Immunol. 164:2000;6461.
108. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57:2000;1045.
109. Sugiura T., Kondo S., Kishimoto S.et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor: comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275:2000;605.
110. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375:1995;143.
111. Bouaboula M., Poinot-Chazel C., Marchand J.et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237:1996;704.
112. 1 receptor knockout mice. Science. 283:1999;401.
113. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780.
114. 2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75:2000;2434.
115. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155.
116. Járai Z., Wagner J.A., Varga K.et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA. 96:1999;14136.
117. Wagner J.A., Varga K., Járai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33:1999;429.
118. Mukhopadhyay S., Chapnick B.M., Howlett A.C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein-dependent and G protein-independent. Am. J. Physiol. 10:2002;1152.
119. Kunos G., Járai Z., Bátkai S. Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids. 108:2000;159.
120. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277.
121. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:2001;191.
122. Gross A., Terraza A., Marchant J.et al. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis. J. Leukocyte Biol. 67:2000;335.
123. 2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta. 1440:1999;266.
124. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659.
125. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989.
126. 2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 339:1997;53.